Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price

CRNXStock

$84.95+72.92%52W

Market Cap$9.01B

P/E—

PEG Ratio—

Div yield—

Beta0.13

CRNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)85.12%

Price vs S&P 500 (4W)1.85%

VGM Score67.58

Book Value / Share (Quarterly)$11.27

P/TBV (Annual)6.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.53%

Cash Flow / Share (Quarterly)$-4.02

Price vs S&P 500 (YTD)70.01%

Net Profit Margin (TTM)-1189.88%

EPS (TTM)$-5.05

10-Day Avg Trading Volume3.02M

EPS Excl Extra (TTM)$-5.05

Revenue Growth (5Y)156.00%

EPS (Annual)$-4.95

ROI (Annual)-46.90%

Gross Margin (Annual)86.02%

Net Profit Margin (5Y Avg)-10707.53%

Cash / Share (Quarterly)$11.40

Revenue Growth QoQ (YoY)2336.28%

ROA (Last FY)-41.32%

Revenue Growth TTM (YoY)2928.45%

EBITD / Share (TTM)$-5.46

ROE (5Y Avg)-38.69%

Operating Margin (TTM)-1302.52%

Cash Flow / Share (Annual)$-4.01

P/B Ratio7.56x

P/B Ratio (Quarterly)3.31x

Net Income / Employee (Annual)$-783,400

EV / Revenue (TTM)212.48x

ROA (TTM)-39.77%

EPS Incl Extra (Annual)$-4.95

Current Ratio (Annual)12.32x

Quick Ratio (Quarterly)15.36x

3-Month Avg Trading Volume3.26M

52-Week Price Return72.92%

Revenue / Employee (TTM)$71,000

Tangible BV / Share (Quarterly)$8.21

P/S Ratio (Annual)1171.10x

Asset Turnover (Annual)0.01x

52-Week High$85.01

Operating Margin (5Y Avg)-11677.88%

EPS Excl Extra (Annual)$-4.95

CapEx CAGR (5Y)97.86%

Tangible BV CAGR (5Y)84.80%

26-Week Price Return95.78%

Quick Ratio (Annual)12.09x

13-Week Price Return138.96%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.57x

Enterprise Value$8.96B

Revenue / Share Growth (5Y)104.27%

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)15.19%

Revenue / Employee (Annual)$13,000

Pretax Margin (Annual)-6043.88%

Cash / Share (Annual)$10.75

3-Month Return Std Dev196.56%

Net Income / Employee (TTM)$-844,500

ROE (Last FY)-46.90%

EPS Basic Excl Extra (Annual)$-4.95

Receivables Turnover (TTM)0.68x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.05

Receivables Turnover (Annual)2.52x

ROI (TTM)-44.22%

P/S Ratio (TTM)213.80x

Pretax Margin (5Y Avg)-10667.85%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$5.87

Price vs S&P 500 (52W)52.74%

Year-to-Date Return82.49%

5-Day Price Return0.11%

EPS Normalized (Annual)$-4.95

ROA (5Y Avg)-34.62%

Net Profit Margin (Annual)-6046.22%

Month-to-Date Return1.71%

Cash Flow / Share (TTM)$-3.61

EBITD / Share (Annual)$-5.45

Operating Margin (Annual)-6714.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-38.69%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.05

P/TBV (Quarterly)3.90x

P/B Ratio (Annual)4.45x

Pretax Margin (TTM)-1189.45%

Book Value / Share (Annual)$10.38

Price vs S&P 500 (13W)137.56%

Beta0.13x

Revenue / Share (TTM)$0.40

ROE (TTM)-44.22%

52-Week Low$32.30

vGradeF

gGradeA

mGradeA

vgmGradeB

CRNX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	-$1.18	-$1.14	+3.73%(+$0.04)
Q1 2026	May 7, 2026	-$1.20	-$1.23	-2.89%(-$0.03)
Q4 2025	Feb 26, 2026	-$1.37	-$1.29	+5.71%(+$0.08)
Q3 2025	Nov 6, 2025	-$1.25	-$1.38	-10.47%(-$0.13)
Q2 2025	Aug 7, 2025	-$1.10	-$1.23	-11.81%(-$0.13)

CRNX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.23

3.48

3.45

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing treatments for rare endocrine diseases and endocrine-related tumors. Its lead product, Palsonify (paltusotine), is an FDA-approved once-daily oral treatment for acromegaly in patients with inadequate response to surgery or for whom surgery is not an option. The pipeline includes late-stage candidate atumelnant for adrenal disorders and CRN09682 targeting specific neuroendocrine tumors.